 LOS ALTOS, Calif., Sept. 7, 2021 PRNewswire -- RenovoRx , Inc. Nasdaq: RNXT, a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510k clearance from the U.S. Food and Drug Administration FDA for its proprietary RenovoCath Delivery System. 